Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | acetolactate synthase 1 catalytic subunit | 0.0329 | 1 | 1 |
Mycobacterium leprae | Probable Acetolactate synthase IlvG (Acetohydroxy-acid synthase)(ALS) | 0.0329 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0106 | 0.1769 | 0.1769 |
Loa Loa (eye worm) | thiamine pyrophosphate enzyme | 0.0189 | 0.481 | 0.8075 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0106 | 0.1769 | 0.5 |
Mycobacterium leprae | PROBABLE ACETOLACTATE SYNTHASE (LARGE SUBUNIT) ILVB (ACETOHYDROXY-ACID SYNTHASE) | 0.0329 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0329 | 1 | 1 |
Plasmodium falciparum | acyl-CoA synthetase | 0.0188 | 0.4798 | 0.5 |
Mycobacterium tuberculosis | Probable acetolactate synthase IlvG (acetohydroxy-acid synthase)(ALS) | 0.0329 | 1 | 1 |
Mycobacterium ulcerans | acetolactate synthase | 0.0188 | 0.4798 | 0.4798 |
Leishmania major | putative pyruvate/indole-pyruvate carboxylase, putative | 0.0188 | 0.4798 | 1 |
Mycobacterium ulcerans | putative oxalyl-CoA decarboxylase | 0.0329 | 1 | 1 |
Mycobacterium ulcerans | pyruvate or indole-3-pyruvate decarboxylase Pdc | 0.0188 | 0.4798 | 0.4798 |
Plasmodium vivax | acyl-CoA synthetase, putative | 0.0188 | 0.4798 | 0.5 |
Schistosoma mansoni | acetolactate synthase | 0.0281 | 0.8231 | 0.5 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0106 | 0.1769 | 0.5 |
Schistosoma mansoni | acetolactate synthase | 0.0281 | 0.8231 | 0.5 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0106 | 0.1769 | 0.5 |
Loa Loa (eye worm) | ILVBL protein | 0.0199 | 0.5202 | 1 |
Mycobacterium tuberculosis | Probable oxalyl-CoA decarboxylase OxcA | 0.0329 | 1 | 1 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0106 | 0.1769 | 0.5 |
Mycobacterium ulcerans | acetolactate synthase large subunit IlvB | 0.0188 | 0.4798 | 0.4798 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.4668 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.